The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
about
Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.Weight loss after laparoscopic adjustable gastric band and resolution of the metabolic syndrome and its components.The therapeutic landscape of non-alcoholic steatohepatitis.Metabolic Disorders and Cancer: Hepatocyte Store-Operated Ca2+ Channels in Nonalcoholic Fatty Liver Disease.
P2860
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@ast
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@en
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@nl
type
label
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@ast
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@en
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@nl
prefLabel
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@ast
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@en
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@nl
P2860
P356
P1476
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
@en
P2093
Barbara McGowan
James Crane
P2860
P304
P356
10.1177/2040622315620180
P407
P577
2016-03-01T00:00:00Z